Penny Powell

Penny Powell


Email [email protected]​

Phone +44 20 7296 5124

Fax +44 20 7296 2001

LanguagesEnglish, French

Practice groupGlobal Regulatory

As partner at Hogan Lovells, Penny has extensive experience in the life sciences, automotive and technology sectors. Understanding her clients’ business requirements is her key to advising clients on their most important commercial transactions, while maintaining a focus on her specialist industry sectors. 

Penny advises on a variety of arrangements that go to the core of clients' on-going business and has particular experience of advising on M&A as well as helping companies structure and negotiate their most complex commercial transactions, including complex joint venture and collaboration arrangements, license and collaboration deals and sourcing/service arrangements. 

Clients turn to Penny for her combined strengths as an M&A and a commercial transactions lawyer as she understands not just the anatomy of getting a deal to completion, but also how a relationship will work out once the ink has dried on the contracts. 

Clients also work with Penny on hybrid transactions such as M&A and licensing transactions, options to acquire companies or technology, development arrangements and product divestitures. She advises clients on transitional service, manufacturing and supply, distribution, promotion, development, and clinical trial agreements and other operational agreements throughout a product life cycle that often accompany transactions.

Focusing on the life sciences, technology and automotive industry sectors gives Penny an in-depth understanding of relevant regulation as well as the practical steps needed to implement it, which can be critical to securing the optimal structural pathway for a transaction.

Education and admissions



Related knowledge

Supply Chain Support

Representative experience

Advising Novartis on the separation of their Manufacturing and Supply arrangements as a consequence of the spin off of Alcon and its listing on SIX Swiss Exchange and New York Stock Exchange.

Advising Alvotech on its exclusive strategic partnership with Teva re five biosimilar product candidates and on manufacturing/licensing arrangements in the MENA region/EU.

Advising Daimler AG on their investments in the Mercedes AMG Petronas F1 Team and previously advising on the Daimler investment in the McLaren Team and Daimler's exit from that arrangement.

Advising Novartis on its pioneering collaboration with Exactmer, CPI, and AstraZeneca to develop an innovative/scalable manufacturing process for oligonucleotides. 

Advising Sandoz AG on an exclusive development and licensing agreement for innovative COPD inhalation devices.

Advising Shire PLC in relation to the acquisition of Shire's oncology business by Servier.

Advising Sandoz AG on a  global collaboration with  Biocon Biologics Limited, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology.

Advising a global technology company on its joint venture with a global pharma company to enable the research, development and commercialisation of bioelectronic medicines.

Advising Novartis on the addition of the fully human monoclonal antibody Ofatumumab to its MS portfolio, through its $1bn acquisition of the rights to the same from GSK.

Advising Novartis on the purchase of GSK’s cancer division and the establishment of the transitional support arrangements for the Parties' joint consumer health joint venture.

Loading data